Tau/α‐synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study
Sign Up to like & getrecommendations! Published in 2017 at "Movement Disorders"
DOI: 10.1002/mds.27001
Abstract: Background: No CSF or plasma biomarker has been validated for diagnosis or progression of PD. read more here.
Keywords: proteins parkinson; ratio inflammatory; synuclein ratio; tau synuclein ... See more keywords
The contribution of β-amyloid, Tau and α-synuclein to blood–brain barrier damage in neurodegenerative disorders
Sign Up to like & getrecommendations! Published in 2024 at "Acta Neuropathologica"
DOI: 10.1007/s00401-024-02696-z
Abstract: Central nervous system (CNS) accumulation of fibrillary deposits made of Amyloid β (Aβ), hyperphosphorylated Tau or α-synuclein (α-syn), present either alone or in the form of mixed pathology, characterizes the most common neurodegenerative diseases (NDDs)… read more here.
Keywords: brain; tau syn; damage; tau ... See more keywords
Amyloid-β, Tau, and α-Synuclein Protein Interactomes as Therapeutic Targets in Neurodegenerative Diseases
Sign Up to like & getrecommendations! Published in 2025 at "Cellular and Molecular Neurobiology"
DOI: 10.1007/s10571-025-01604-7
Abstract: Alzheimer’s and Parkinson’s disease are the most prevalent neurological diseases. Amyloid-β, tau, and α-synuclein proteins are known to be implicated in neurodegenerative disease (NDD). Elucidation of precise therapeutic targets remains a challenge. Therefore, the identification… read more here.
Keywords: therapeutic targets; protein; tau synuclein; amyloid tau ... See more keywords
O-GlcNAcase Inhibitor ASN90 is a Multimodal Drug Candidate for Tau and α-Synuclein Proteinopathies.
Sign Up to like & getrecommendations! Published in 2022 at "ACS chemical neuroscience"
DOI: 10.1021/acschemneuro.2c00057
Abstract: Neurodegenerative proteinopathies are characterized by the intracellular formation of insoluble and toxic protein aggregates in the brain that are closely linked to disease progression. In Alzheimer's disease and in rare tauopathies, aggregation of the microtubule-associated… read more here.
Keywords: inhibitor asn90; pathology; tau synuclein; synuclein ... See more keywords
A novel lncRNA FAM151B-DT regulates degradation of aggregation prone proteins
Sign Up to like & getrecommendations! Published in 2025 at "Molecular Psychiatry"
DOI: 10.1038/s41380-025-03277-6
Abstract: Neurodegenerative diseases share common features of protein aggregation along with other pleiotropic traits, including shifts in transcriptional patterns, neuroinflammation, disruption in synaptic signaling, mitochondrial dysfunction, oxidative stress, and impaired clearance mechanisms like autophagy. However, key… read more here.
Keywords: novel lncrna; lncrna fam151b; tau synuclein; aggregation ... See more keywords
Interaction of misfolded proteins and mitochondria in neurodegenerative disorders.
Sign Up to like & getrecommendations! Published in 2017 at "Biochemical Society transactions"
DOI: 10.1042/bst20170024
Abstract: The number of the people affected by neurodegenerative disorders is growing dramatically due to the ageing of population. The major neurodegenerative diseases share some common pathological features including the involvement of mitochondria in the mechanism… read more here.
Keywords: proteins mitochondria; amyloid tau; neurodegenerative disorders; tau synuclein ... See more keywords
Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.
Sign Up to like & getrecommendations! Published in 2022 at "Human molecular genetics"
DOI: 10.1093/hmg/ddac038
Abstract: Cognitive impairment is a common non-motor complication of Parkinson disease (PD). Glucocerebrosidase gene (GBA1) variants are found in 10-15% of PD cases and are numerically the most important risk factor for PD and dementia with… read more here.
Keywords: synuclein tau; n370s gba1; cholinergic neurons; gba1 mutation ... See more keywords
Tau- and α-synuclein-targeted gold nanoparticles: applications, opportunities, and future outlooks in the diagnosis and therapy of neurodegenerative diseases
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Nanobiotechnology"
DOI: 10.1186/s12951-024-02526-0
Abstract: The use of nanomaterials in medicine offers multiple opportunities to address neurodegenerative disorders such as Alzheimer's and Parkinson's disease. These diseases are a significant burden for society and the health system, affecting millions of people… read more here.
Keywords: use; diagnosis therapy; tau synuclein; gold ... See more keywords
Dementia with lewy bodies patients with high tau levels display unique proteome profiles
Sign Up to like & getrecommendations! Published in 2024 at "Molecular Neurodegeneration"
DOI: 10.1186/s13024-024-00782-0
Abstract: Clinical studies have long observed that neurodegenerative disorders display a range of symptoms and pathological features and, in some cases, overlap, suggesting that these diseases exist on a spectrum. Dementia with Lewy Bodies (DLB), a… read more here.
Keywords: abundance; lewy bodies; pathology; tau ... See more keywords
NMDA and AMPA Receptors at Synapses: Novel Targets for Tau and α-Synuclein Proteinopathies
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10071550
Abstract: A prominent feature of neurodegenerative diseases is synaptic dysfunction and spine loss as early signs of neurodegeneration. In this context, accumulation of misfolded proteins has been identified as one of the most common causes driving… read more here.
Keywords: misfolded proteins; ampa receptors; synapses novel; tau synuclein ... See more keywords